SEARCH

Search Details

HAYASHI Tomohiro
Graduate School of Medicine / Faculty of Medical Sciences
Assistant Professor

Researcher basic information

■ Research Keyword
  • 循環器
  • 総合診療
  • 地域医療
  • 免疫学
■ Research Areas
  • Life sciences / Internal medicine - General / Heart failure, Cardiomyopathy, Immunology, Atherosclerosis
■ Committee History
  • Dec. 2025 - Present, Frontiers in Cardiovascular Medicine, Associate Editor
  • Oct. 2025 - Present, 日本腫瘍循環器学会, JOCS-NEXT (日本腫瘍循環器学会 若手の会) 研究班員
  • Sep. 2023 - Jul. 2024, Frontiers in Cardiovascular Medicine, "Reviews in Takotsubo Syndrome" Topic Editor

Research activity information

■ Award
  • Mar. 2022 日本循環器学会, YIA (Clinical Research部門) 優秀賞
    林 友鴻

  • Jan. 2020 公益財団法人 上原記念生命科学財団, リサーチフェローシップ
    林 友鴻

  • Feb. 2019 公益財団法人 ライフサイエンス振興財団, 国際交流援助 (調査・研究)
    林 友鴻

  • Dec. 2018 公益財団法人 MSD生命科学財団, 海外留学助成 生活習慣病領域
    林 友鴻

  • Sep. 2018 公益財団法人 持田記念医学薬学振興財団, 留学補助金
    林 友鴻

  • Jul. 2018 日本動脈硬化学会, 第26回 若手研究者奨励賞 (論文賞)
    林 友鴻

  • Nov. 2016 ヒューマン・メタボローム・テクノロジーズ, メタボロミクス先導研究助成 奨励賞
    林 友鴻

■ Paper
  • Yoshitaka Haino, Tsuneaki Kenzaka, Tomohiro Hayashi, Kimikazu Yakushijin
    Mar. 2026, Reports
    Scientific journal

  • Tsuneaki Kenzaka, Naoya Mizutani, Tomohiro Hayashi, Ayako Kumabe
    Feb. 2026, Healthcare
    Scientific journal

  • Shinnosuke Tsukamoto, Kensuke Matsumoto, Tomohiro Hayashi, Akitaka Yamada, Satoru Kawasaki
    BACKGROUND: Traumatic mitral regurgitation (MR) is an exceptionally rare complication associated with blunt chest trauma, particularly following relatively low-impact injuries. In the critical and chaotic settings of polytrauma, its diagnosis is often delayed and can easily be overlooked. This oversight can lead to progressive haemodynamic deterioration and, ultimately, fatal outcomes. CASE SUMMARY: A 73-year-old man sustained blunt chest trauma after falling ∼2.5 m from a truck bed. Initial assessment revealed a left haemopneumothorax and multiple rib fractures, with no audible heart murmur or signs of haemodynamic compromise. A chest drain was inserted, and he was discharged after conservative management. However, 3 weeks post-injury, a Grade III systolic regurgitant murmur was newly detected. Transthoracic and transoesophageal echocardiography revealed severe eccentric MR due to posterior mitral valve prolapse caused by chordal rupture. Intraoperative inspection confirmed a P2 chordal rupture with myxomatous degeneration. The patient underwent successful mitral valve repair and had an uneventful postoperative recovery. DISCUSSION: This case highlights that traumatic MR, though extremely rare, can occur even after relatively minor trauma in elderly individuals, potentially due to underlying degenerative changes. Clinical signs of acute MR can be obscured by coexisting injuries, and auscultatory findings may only become apparent after these conditions have been treated. While echocardiography is crucial for identifying traumatic valvular dysfunction, its effectiveness can be limited by various factors associated with polytrauma. Therefore, a high index of suspicion is essential to prevent overlooking this potentially life-threatening complication in cases of blunt chest trauma.
    Sep. 2025, European heart journal. Case reports, 9(9) (9), ytaf399, English, International magazine
    Scientific journal

  • Yuya Suzuki, Takuo Emoto, Shunsuke Sato, Takeshi Yoshida, Mitsuhiko Shoda, Hiromi Endoh, Manabu Nagao, Tomoyo Hamana, Taishi Inoue, Tomohiro Hayashi, Eriko Nitta, Hiroki Konishi, Kunihiko Kiuchi, Mitsuru Takami, Kimitake Imamura, Masayuki Taniguchi, Masatoshi Inoue, Toshihiro Nakamura, Yusuke Sonoda, Hiroyuki Takahara, Kazutaka Nakasone, Kyoko Yamamoto, Kenichi Tani, Hidehiro Iwai, Yusuke Nakanishi, Shogo Yonehara, Atsushi Murakami, Ryuji Toh, Takenao Ohkawa, Tomoyuki Furuyashiki, Ryo Nitta, Tomoya Yamashita, Ken-ichi Hirata, Koji Fukuzawa
    May 2025, Communications Biology
    Scientific journal

  • Yuya Suzuki, Takuo Emoto, Shunsuke Sato, Takeshi Yoshida, Mitsuhiko Shoda, Hiromi Endoh, Manabu Nagao, Tomoyo Hamana, Taishi Inoue, Tomohiro Hayashi, Eriko Nitta, Hiroki Konishi, Kunihiko Kiuchi, Mitsuru Takami, Kimitake Imamura, Masayuki Taniguchi, Masatoshi Inoue, Toshihiro Nakamura, Yusuke Sonoda, Hiroyuki Takahara, Kazutaka Nakasone, Kyoko Yamamoto, Kenichi Tani, Hidehiro Iwai, Yusuke Nakanishi, Shogo Yonehara, Atsushi Murakami, Ryuji Toh, Takenao Ohkawa, Tomoyuki Furuyashiki, Ryo Nitta, Tomoya Yamashita, Ken-ichi Hirata, Koji Fukuzawa
    Dec. 2024, Communications Biology
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Miki Nanyoshi, Tomohiro Hayashi, Ryu Sugimoto, Hogara Nishisaki, Tsuneaki Kenzaka
    BACKGROUND: Kounis syndrome is defined as the concurrence of acute coronary syndromes in the setting of allergic or anaphylactic reactions. It primarily affects men aged 40-70 years and is often associated with chest pain. This syndrome is often unrecognized and undiagnosed in clinical practice due to a low level of awareness. Herein, we present a case of type I Kounis syndrome in a young woman without chest pain. CASE PRESENTATION: A 28-year-old Japanese woman with a history of atopic dermatitis received a glycyrrhizin, glutathione, and neurotropin preparation (a preparation of inflamed skin extract from rabbits inoculated with vaccinia virus) at a dermatology clinic to treat pruritus caused by atopic dermatitis. Immediately after the administration, the patient developed abdominal pain and generalized body wheals. The patient was diagnosed with anaphylaxis and was transported to our hospital. She had no chest pain on arrival at our hospital; however, a 12-lead electrocardiogram showed ST elevation in leads I, aVL, V2, and V3, and an echocardiogram showed decreased wall motion in the anterior and lateral walls of the left ventricle. Sublingual nitroglycerin administration improved ST-segment elevation and left ventricular wall motion abnormalities. The patient underwent emergency coronary angiography, which revealed no significant stenosis, and was diagnosed with type I Kounis syndrome. CONCLUSION: Kounis syndrome without chest pain is rare in young women. Since it can be fatal in cases with severe allergic symptoms such as anaphylaxis, the possibility of concurrent acute coronary syndrome should be considered when treating systemic allergic reactions, regardless of age, sex, or the presence or absence of chest symptoms.
    Sep. 2024, BMC cardiovascular disorders, 24(1) (1), 467 - 467, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomohiro Hayashi
    2024, Frontiers in cardiovascular medicine, 11, 1446689 - 1446689, English, International magazine

  • Tomohiro Hayashi, Kenji Rowel Q Lim, Attila Kovacs, Douglas L Mann
    It is unclear how the immune system initiates effective tissue repair responses without also simultaneously activating adaptive immune responses to self-antigens released by damaged or necrotic cells. We studied the role of repetitive adrenergic mediated stress on cardiac injury wild-type and programmed death-1-deficient (PD-1-/-) mice treated with 3 intraperitoneal low doses of isoproterenol followed by an intraperitoneal injection of high-dose ISO 7 days later (ISOprimed/ISOinjury). Repetitive adrenergic stress in ISOprimed/ISOinjury PD-1-/- mice resulted in a persistent dysregulated myocardial inflammatory response characterized by the expansion of autoreactive effector CD8+ T cells, increased cardiac hypertrophy, mild left ventricular dysfunction, and increased lethality when compared with ISOprimed/ISOinjury wild-type mice.
    Dec. 2023, JACC. Basic to translational science, 8(12) (12), 1503 - 1517, English, International magazine
    Scientific journal

  • Sajal K Tiwary, Tomohiro Hayashi, Attila Kovacs, Douglas L Mann
    Whereas the innate immune response to an initial episode of cardiac injury has been studied extensively, the response of the immune system to recurrent cardiac tissue injury is not well understood. Specifically, it is not known whether the immune system adapts to the initial episode of cardiac injury and whether any adaptations that occur lead to immune cell hypo-responsiveness or, alternatively, immune cell hyper-responsiveness. Here, we studied the role of adrenergic-mediated stress using a simple model of reversible stress-induced cardiomyopathy, and show that isoproterenol-induced tissue injury and inflammation are sufficient to protect the heart from the myopathic effects of a subsequent exposure to isoproterenol. Remarkably, pharmacological depletion of macrophages partially attenuated the isoproterenol-induced cytoprotective response, suggesting that immune-mediated tissue repair mechanisms confer tolerance to subsequent tissue damage.
    Jul. 2023, JACC. Basic to translational science, 8(7) (7), 783 - 797, English, International magazine
    Scientific journal

  • Tomohiro Hayashi, Sajal K Tiwary, Kenji Rowel Q Lim, Cibele Rocha-Resende, Douglas L Mann
    May 2023, American journal of physiology. Heart and circulatory physiology, 324(5) (5), H655-H656, English, International magazine

  • Xiqiang Wang, Xiude Fan, Yanpeng Ma, Ling Zhu, Ting Wang, Jing Liu, Chengfeng Liu, Tomohiro Hayashi, Gongchang Guan, Shuo Pan, Zhongwei Liu, Junkui Wang
    AIMS: Mitral regurgitation (MR) is the most prevalent form of valvular heart disease. Transcatheter mitral valve repair (TMVr) and transcatheter mitral valve replacement (TMVR) have recently emerged as alternatives to open heart surgical repair or replacement. However, studies on the comparative outcomes of TMVr and TMVR are limited. This study aims to compare the demographics, complications and outcomes of TMVr and TMVR based on a real-world investigation of the National Inpatient Sample (NIS) database. METHODS AND RESULTS: From 2016-2018 in the NIS database, a total of 210 and 3370 patients who underwent TMVR and TMVr, respectively, were selected. The mean age of the patients was 75.99 years (TMVr) and 69.6 years (TMVR) (p <0.01). The mortality of patients who received TMVR was higher compared to that of patients who were treated with TMVr (8.1 vs. 1.9%, p <0.01). The patients who underwent TMVR were more likely to suffer perioperative complications including blood transfusions (16.2 vs. 5.0%, p <0.01) and acute kidney injury (22.9 vs. 13.3%, p <0.01). The average cost of treatment was higher (USD $278864 vs. USD $216845, p <0.01), and the average duration of hospitalization was longer (8.73 vs. 4.17 d, p <0.01) for TMVR compared to TMVr. When taking into account perioperative comorbidities and other factors, TMVR was associated with a worse adjusted in-hospital mortality (odds ratio [OR], 3.307 [95% CI, 1.533-7.136]; p <0.01). CONCLUSION: TMVr is associated with lower mortality, peri-procedural morbidity, and resource use compared to TMVR. A patient-centered approach can help guide decision-making about the choice of intervention for the individual patient and more studies evaluating the long-term outcomes and durability of TMVR are needed at present.
    Feb. 2023, Archives of medical research, 54(2) (2), 145 - 151, English, International magazine
    Scientific journal

  • Tomohiro Hayashi, Sajal K. Tiwary, Kenji Rowel Q. Lim, Cibele Rocha-Resende, Attila Kovacs, Carla Weinheimer, Douglas L. Mann
    Despite the many advantages of isoproterenol (Iso)-induced models of cardiomyopathy, the extant literature suggests that the reproducibility of the Iso-induced stress cardiomyopathy phenotype varies considerably depending on the dose of Iso used, the mode of administration of Iso (subcutaneous vs. intraperitoneal), and the species of the animal that is being studied. Recently, we have shown that a single injection of Iso into female C57BL/6J mice provokes transient myocardial injury that is characterized by a brisk release of troponin I within 1 h, as well as a self-limited myocardial inflammatory response that is associated with increased myocardial tissue edema, inferoapical regional left ventricular (LV) wall motion abnormalities, and a transient decrease in global LV function, which were completely recovered by day 7 after the Iso injection (i.e., stress-induced reversible cardiomyopathy). Here we expand upon this initial report in this model by demonstrating important sexually dimorphic differences in the response to Iso-induced tissue injury, the ensuing myocardial inflammatory response, and changes in LV structure and function. We also provide information with respect to enhancing the reproducibility in this model by optimizing animal welfare during the procedure. The acute Iso-induced myocardial injury model provides a low-cost, relatively high-throughput small-animal model that mimics human disease (e.g., Takotsubo cardiomyopathy). Given that the model can be performed in different genetic backgrounds, as well as different experimental conditions, the acute Iso injury model should provide the cardiovascular community with a valuable nonsurgical animal model for understanding the myocardial response to tissue injury.NEW & NOTEWORTHY The present study highlights the importance of sexual dimorphism with respect to isoproterenol injury, as well as the importance of animal handling and welfare to obtain reproducible results from investigator to investigator. Based on serial observations of animal recovery (locomotor activity and grooming behavior), troponin I release, and inflammation, we identified that the method used to restrain the mice for the intraperitoneal injection was the single greatest source of variability in this model.
    Feb. 2023, American Journal of Physiology-Heart and Circulatory Physiology, 324(2) (2), H229-H240, English, International magazine
    Scientific journal

  • Kenji Rowel Q Lim, Douglas L Mann, Tsuneaki Kenzaka, Tomohiro Hayashi
    Takotsubo syndrome (TTS) is a disorder characterized by transient cardiac dysfunction with ventricular regional wall motion abnormalities, primarily thought to be caused by the effects of a sudden catecholamine surge on the heart. Although the majority of patients exhibit prompt recovery of their cardiac dysfunction, TTS remains associated with increased mortality rates acutely and at long-term, and there is currently no cure for TTS. Inflammation has been shown to play a key role in determining outcomes in TTS patients, as well as in the early pathogenesis of the disorder. There are also cases of TTS patients that have been successfully treated with anti-inflammatory therapies, supporting the importance of the inflammatory response in TTS. In this article, we provide a comprehensive review of the available clinical and pre-clinical literature on the immune response in TTS, in an effort to not only better understand the pathophysiology of TTS but also to generate insights on the treatment of patients with this disorder.
    2023, Frontiers in immunology, 14, 1254011 - 1254011, English, International magazine
    Scientific journal

  • Tomohiro Hayashi, Sajal K. Tiwary, Kory J. Lavine, Sandeep Acharya, Michael Brent, Luigi Adamo, Attila Kovacs, Douglas L. Mann
    Elsevier {BV}, Nov. 2022, JACC: Basic to Translational Science, 7(11) (11), 1120 - 1139, English
    Scientific journal

  • Xiqiang Wang, Xiude Fan, Qihui Wu, Jing Liu, Linyan Wei, Dandan Yang, Xiang Bu, Xiaoxiang Liu, Aiqun Ma, Tomohiro Hayashi, Gongchang Guan, Yu Xiang, Shuang Shi, Junkui Wang, Jiansong Fang
    BACKGROUND AND AIMS: Heart failure with reduced ejection fraction (HFrEF) still carries a high risk for a sustained decrease in left ventricular ejection fraction (LVEF) even with the optimal medical therapy. Currently, there is no effective tool to stratify these patients according to their recovery potential. We tested the hypothesis that uric acid (UA) could predict recovery of LVEF and prognosis of HFrEF patients and attempted to explore mechanistic relationship between hyperuricemia and HFrEF. METHODS: HFrEF patients with hyperuricemia were selected from the National Inpatient Sample (NIS) 2016-2018 database and our Xianyang prospective cohort study. Demographics, cardiac risk factors, and cardiovascular events were identified. Network-based analysis was utilized to examine the relationship between recovery of LVEF and hyperuricemia, and we further elucidated the underlying mechanisms for the impact of hyperuricemia on HFrEF. RESULTS: After adjusting confounding factors by propensity score matching, hyperuricemia was a determinant of HFrEF [OR 1.247 (1.172-1.328); P < 0.001] of NIS dataset. In Xianyang prospective cohort study, hyperuricemia is a significant and independent risk factor for all-cause death (adjusted HR 2.387, 95% CI 1.141-4.993; P = 0.021), heart failure readmission (adjusted HR 1.848, 95% CI 1.048-3.259; P = 0.034), and composite events (adjusted HR 1.706, 95% CI 1.001-2.906; P = 0.049) in HFrEF patients. UA value at baseline was negatively correlated to LVEF of follow-ups (r = -0.19; P = 0.046). Cutoff UA value of 312.5 μmmol/L at baseline can work as a predictor of LVEF recovery during follow-up, with the sensitivity of 66.7%, the specificity of 35.1%, and the accuracy of 0.668 (95% CI, 0.561-0.775; P = 0.006). Moreover, gene overlap analysis and network proximity analysis demonstrated a strong correlation between HFrEF and Hyperuricemia. CONCLUSION: Lower baseline UA value predicted the LVEF recovery and less long-term adverse events in HFrEF patients. Our results provide new insights into underlying mechanistic relationship between hyperuricemia and HFrEF.
    2022, Frontiers in cardiovascular medicine, 9, 853870 - 853870, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Aims: Circulating amino acid (AA) abnormalities serve as predictors of adverse outcomes in patients with heart failure (HF). However, the role of the gut microbiota in AA disturbances remains unknown. Thus, we investigated gut microbial functions and their associations with AA metabolic alterations in patients with HF. Methods and Results: We performed whole-genome shotgun sequencing of fecal samples and mass spectrometry-based profiling of AAs in patients with compensated HF. Plasma levels of total essential AAs (EAAs) and histidine were significantly lower in patients with HF than in control subjects. HF patients also displayed increased and decreased abundance of gut microbial genes involved in the degradation and biosynthesis, respectively, of EAAs, including branched-chain AAs (BCAAs) and histidine. Importantly, a significant positive correlation was observed between the abundance of microbial genes involved in BCAA biosynthesis and plasma BCAA levels in patients with HF, but not in controls. Moreover, network analysis revealed that the depletion of Eubacterium and Prevotella, which harbor genes for BCAA and histidine biosynthesis, contributed to decreased abundance of microbial genes involved in the biosynthesis of those EAAs in patients with HF. Conclusions: The present study demonstrated the relationship between gut microbiota and AA metabolic disturbances in patients with HF.
    Nov. 2021, Frontiers in cardiovascular medicine, 8, 789325 - 789325, English, International magazine
    Scientific journal

  • Tomohiro Hayashi

    Aims

    The methodology to distinguish between the heart failure (HF) with recovered ejection fraction (HFrecEF) and those with continuously reduced ejection fraction (EF) (HFcrEF) on admission has not been established. We recently demonstrated that the ratio of plasma levels of pro-B-type natriuretic peptide (proBNP) to total BNP (proBNP plus mature BNP) is decreased on admission in patients with mild acute HF, but not in severe acute HF as a compensatory mechanism for activating cyclic GMP via increases of bioactive mature BNP. We aimed to test the hypothesis that the ratio of bioactive mature BNP to total BNP is associated with reverse remodelling capacity in patients with HF with reduced EF.

    Methods and results

    Plasma proBNP and total BNP were measured in patients with acute decompensated HF by using specific and sensitive enzyme immunochemiluminescent assay. Estimated percent mature BNP (%emBNP) was calculated as ([total BNP - proBNP]/total BNP) × 100. We retrospectively identified the patients with reduced EF (≤40%, on admission) who had echocardiographic data after discharge (n = 93). We defined patients with increased EF by >10% during the follow-up term (median, 545 days) after the admission as HFrecEF group. We compared patient characteristics, %emBNP, and other biomarkers between HFrecEF and HFcrEF. Of the enrolled patients with HFrecEF (n = 32) and HFcrEF (n = 61), on admission, %emBNP was significantly higher in HFrecEF than in HFcrEF (44.1% vs. 36.9%; P < 0.05). There were no significant differences in left ventricular EF on admission between the two groups. The univariate analysis revealed that %emBNP on admission was associated with HFrecEF occurrence rate (P < 0.05), in contrast both total BNP and high-sensitive cardiac troponin-T levels were not associated with HFrecEF occurrence rate.

    Conclusions

    The ratio of mature BNP to total BNP in plasma at the time of hospital admission may be predictive of left ventricular contractile recovery. Preservation of the capacity to convert proBNP to mature BNP, but not myocardial injury itself, is associated with future ventricular contractile recovery.
    Nov. 2021, ESC heart failure, 8(6) (6), 5617 - 5621, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Objective: The global trends in myocarditis burden over the past two decades remain poorly understood and might be increasing during the coronavirus disease 2019 (COVID-19) worldwide pandemic. This study aimed to provide comprehensive estimates of the incidence, mortality, and disability-adjusted life years (DALYs) for myocarditis globally from 1990 to 2017. Methods: Data regarding the incidence, mortality, DALY, and estimated annual percentage change (EAPC) between 1990 and 2017 for myocarditis worldwide were collected and calculated from the 2017 Global Burden of Disease study. We additionally calculated the myocarditis burden distribution based on the Socio-Demographic Index (SDI) quintile and Human Development Index (HDI). Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. The number of deaths due to myocarditis increased gradually from 27,120 in 1990 to 46,490 in 2017. The middle SDI quintile showed the highest number of myocarditis-related deaths. On the contrary, the global age-standardized death rate (ASDR) decreased with an overall EAPC of -1.4 [95% uncertainty interval (UI) = -1.8 to -1.0]. Similar to ASDR, the global age-standardized DALY rate also declined, with an EAPC of -1.50 (95% UI = -2.30 to -0.8) from 1990 to 2017. However, there was a 12.1% increase in the number of DALYs in the past 28 years; the middle SDI and low-middle SDI quintiles contributed the most to the DALY number in 2017. We also observed significant positive correlations between the EPAC of age-standardized rate and HDI for both death and DALY in 2017. Conclusions: Globally, the ASIR, ASDR, and age-standardized DALY rate of myocarditis decreased slightly from 1990 to 2017. The middle SDI quintile had the highest level of ASIR, ASDR, and age-standardized DALY rate, indicating that targeted control should be developed to reduce the myocarditis burden especially based on the regional socioeconomic status. Our findings also provide a platform for further investigation into the myocarditis burden in the era of COVID-19.
    Jul. 2021, Frontiers in cardiovascular medicine
    Scientific journal

  • Tomohiro Hayashi

    Background

    We had previously reported an increase in trimethylamine N-oxide (TMAO) levels in patients with both compensated and decompensated heart failure (HF) and alteration in gut microbiota composition using 16S rRNA gene amplicon analysis. Although a metagenome-wide analysis showed that choline-TMA lyase levels increased in HF patients, which TMA generation pathway from choline, carnitine, or betaine contributes to the increase in TMAO levels in HF needs to be elucidated.

    Methods

    We conducted a metagenome-wide shotgun sequencing analysis of gut microbiota and measured the TMAO levels in plasma of 22 HF patients during the compensated phase and 11 age-, sex-, and comorbidity-matched control subjects, whose gut microbiota compositions were reported in a previous 16S rRNA-based analysis.

    Results

    The abundance of cntA/B was positively correlated with TMAO, especially in HF patients, whereas that of cutC/D or betaine reductase was not correlated either in controls or HF patients. The abundance of cntA/B was mainly derived from the genera Escherichia and Klebsiella either in controls or HF patients.

    Conclusion

    TMAO levels in plasma depend on the abundance of cntA/B in HF. Although it is difficult to exclude the involvement of confounding factors, microbial dysbiosis connecting the abundance of cntA/B in the gut and the increase of TMAO in plasma can be a therapeutic target for HF.
    Jun. 2021, International journal of cardiology
    Scientific journal

  • Tomohiro Hayashi
    Faecal lipopolysaccharides (LPS) have attracted attention as potent elements to explain a correlation between the gut microbiota and cardiovascular disease (CVD) progression. However, the underlying mechanism of how specific gut bacteria contribute to faecal LPS levels remains unclear. We retrospectively analysed the data of 92 patients and found that the abundance of the genus Bacteroides was significantly and negatively correlated with faecal LPS levels. The controls showed a higher abundance of Bacteroides than that in the patients with CVD. The endotoxin units of the Bacteroides LPS, as determined by the limulus amoebocyte lysate (LAL) tests, were drastically lower than those of the Escherichia coli LPS; similarly, the Bacteroides LPS induced relatively low levels of pro-inflammatory cytokine production and did not induce sepsis in mice. Fermenting patient faecal samples in a single-batch fermentation system with Bacteroides probiotics led to a significant increase in the Bacteroides abundance, suggesting that the human gut microbiota could be manipulated toward decreasing the faecal LPS levels. In the clinical perspective, Bacteroides decrease faecal LPS levels because of their reduced LAL activity; therefore, increasing Bacteroides abundance might serve as a novel therapeutic approach to prevent CVD via reducing faecal LPS levels and suppressing immune responses.
    Aug. 2020, Scientific reports, 10(1) (1), 13009 - 13009, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Atrial fibrillation (AF) reduces the quality of life by triggering stroke and heart failure. The association between AF onset and gut metabolites suggests a causal relationship between AF and gut microbiota dysbiosis; however, the relationship remains poorly understood. We prospectively enrolled 34 hospitalized patients with AF and 66 age-, sex-, and comorbidity-matched control subjects without a history of AF. Gut microbial compositions were evaluated by amplicon sequencing targeting the 16S ribosomal RNA gene. We assessed differences in dietary habits by using a brief-type self-administered diet history questionnaire (BDHQ). Gut microbial richness was lower in AF patients, although the diversity of gut microbiota did not differ between the two groups. At the genus level, Enterobacter was depleted, while Parabacteroides, Lachnoclostridium, Streptococcus, and Alistipes were enriched in AF patients compared to control subjects. The BDHQ revealed that the intake of n-3 polyunsaturated fatty acids and eicosadienoic acid was higher in AF patients. Our results suggested that AF patients had altered gut microbial composition in connection with dietary habits.
    Jul. 2020, Heart and vessels
    Scientific journal

  • 【生活習慣病と腸内細菌】循環器疾患と腸内細菌叢
    山下 智也, 吉田 尚史, 林 友鴻, 田畑 論子, 江本 拓央, 平田 健一
    (株)ライフ・サイエンス, Mar. 2020, Progress in Medicine, 40(3) (3), 223 - 229, Japanese
    [Refereed]

  • Tomohiro Hayashi
    Background Early detection for worsening renal function (WRF) is indispensable in patients with acute decompensated heart failure (HF). We tested the hypothesis that the difference in the circulating levels of each B-type or brain natriuretic peptide (BNP) molecular form is associated with the occurrence of WRF. Methods and Results Circulating levels of proBNP, the NT-proBNP (N-terminal proBNP), and total BNP (proBNP+mature BNP) were prospectively measured in patients with acute decompensated HF using specific and sensitive enzyme immunochemiluminescent assays. An estimated mature BNP (emBNP) concentration was calculated by subtracting proBNP levels from total BNP levels. WRF was defined as a >20% decrease in the estimated glomerular filtration rate during the hospitalization. One-way repeated-measures ANOVA was used to compare the changes of variables between the patients with and without WRF. In patients with acute decompensated HF (New York Heart Association class III-IV; 96%) hospitalized for HF, NT-proBNP levels did not differ during the hospitalization between patients with and without WRF (n=42 and 140, respectively). By contrast, emBNP levels were lower in patients with WRF than in those without WRF on day 3 after admission. NT-proBNP/emBNP molar ratios were elevated on day 3 after admission in the patients with WRF, before estimated glomerular filtration rate declined, but were unchanged in patients without WRF. On day 3 after hospital admission, NT-proBNP/emBNP ratios were strongly associated with percentage decreases in estimated glomerular filtration rate. Conclusions These findings suggest that elevation of NT-proBNP/emBNP ratio precedes WRF in patients with acute HF and can be a potentially useful biomarker for risk stratification of cardiorenal syndrome.
    Aug. 2019, Journal of the American Heart Association, 8(17) (17), e011468, English, International magazine
    Scientific journal

  • Tomohiro Hayashi

    Aims

    There are significant differences in how atrial (A-type) and B-type natriuretic peptide (ANP and BNP) are secreted and metabolised, but there is little information available about the relative clinical significance of the two peptides. The aim of the present study was to investigate: (1) the association between the circulating level of each ANP molecular form and patient clinical background and (2) their prognostic power for patients with acute decompensated heart failure (ADHF).

    Methods

    We used specific chemiluminescence enzyme immunoassays to prospectively evaluate the levels of six bioactive molecular forms of ANP (pro-ANP, β-ANP and total ANP) and BNP (pro-BNP, N-terminal pro-BNP (NT-pro-BNP) and total BNP) in plasma samples collected from 173 patients with ADHF on their hospital admission.

    Results

    We found that pro-ANP levels were strongly associated with left ventricular (LV) size and ejection fraction (p<0.001), but were not associated with left atrial size. Percent pro-ANP ([pro-ANP/total ANP]x100) was also associated with LV size and function. During the follow-up term (median: 469 days), composite adverse events (all causes of death or rehospitalisation for HF) occurred in 67 patients (38.7 %). Pro-ANP was significantly associated with composite adverse events even after adjusting by estimated glomerular filtration rate (eGFR) (p<0.05). In contrast, NT-pro-BNP was not independent of eGFR in the multivariate analysis.

    Conclusion

    Circulating levels of pro-ANP are strongly associated with LV function and clinical outcomes of patients with ADHF. These findings suggest that during the acute phases of HF, pro-ANP has a prognostic power comparable with NT-pro-BNP independently of renal function.
    Jul. 2019, Open heart, 6(2) (2), e001072, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Vascular inflammation via T-cell-mediated immune responses has been shown to be critically involved in the pathogenesis of abdominal aortic aneurysm (AAA). T-cell coinhibitory molecule cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is known to act as a potent negative regulator of immune responses. However, the role of this molecule in the development of AAA remains completely unknown. We determined the effects of CTLA-4 overexpression on experimental AAA. We continuously infused CTLA-4 transgenic (CTLA-4-Tg)/apolipoprotein E-deficient (Apoe-/-) mice or control Apoe-/- mice fed a high-cholesterol diet with angiotensin II by implanting osmotic mini-pumps and evaluated the development of AAA. Ninety percent of angiotensin II-infused mice developed AAA, with 50% mortality because of aneurysm rupture. Overexpression of CTLA-4 significantly reduced the incidence (66%), mortality (26%), and diameter of AAA. These protective effects were associated with a decreased number of effector CD4+ T cells and the downregulated expression of costimulatory molecules CD80 and CD86, ligands for CTLA-4, on CD11c+ dendritic cells in lymphoid tissues. CTLA-4-Tg/Apoe-/- mice had reduced accumulation of macrophages and CD4+ T cells, leading to attenuated aortic inflammation, preserved vessel integrity, and decreased susceptibility to AAA and aortic rupture. Our findings suggest T-cell coinhibitory molecule CTLA-4 as a novel therapeutic target for AAA.
    May 2019, Scientific reports, 9(1) (1), 8065 - 8065, English, International magazine
    Scientific journal

  • Tomohiro Hayashi

    Aim

    Bacteroides vulgatus and B. dorei have a protective effect against atherosclerosis, suggesting that expansion of these species in the gut microbiota could help patients with coronary artery disease (CAD). This study aimed to investigate the effect of resistant starch (RS) on the gut microbiota and its metabolites in fecal sample cultures from patients with CAD and individuals without CAD, using a single-batch fermentation system.

    Methods

    Fecal samples from 11 patients with CAD and 10 individuals without CAD were fermented for 30 h with or without RS in the Kobe University Human Intestinal Microbiota Model (KUHIMM). Gut microbiota and the abundance of B. vulgatus and B. dorei were analyzed using 16S ribosomal ribonucleic acid (rRNA) gene sequencing and the quantitative polymerase chain reaction. Short-chain fatty acids were analyzed using high-performance liquid chromatography.

    Results

    Gut microbial analysis showed significantly lower levels of B. vulgatus and B. dorei in the original fecal samples from patients with CAD, which was simulated after 30 h of fermentation in the KUHIMM. Although RS significantly increased the absolute numbers of B. vulgatus and B. dorei, and butyrate levels in CAD fecal sample cultures, the numbers varied among each patient.

    Conclusions

    The effect of RS on gut microbiota and its metabolites in the KUHIMM varied between CAD and non-CAD fecal sample cultures. The KUHIMM may be useful for preclinical evaluations of the effects of RS on the gut microbiota and its metabolites.
    Dec. 2018, Journal of atherosclerosis and thrombosis, 26(8) (8), 705 - 719, English, Domestic magazine
    Scientific journal

  • Tomohiro Hayashi

    Background

    Gut microbiome composition or circulating microbiome-related metabolites in patients with heart failure (HF) have not been investigated at different time points (i.e., in the decompensated (Decomp) and compensated (Comp) phases). Methods and Results: We prospectively enrolled 22 patients admitted for HF and 11 age-, sex-, and comorbidity-matched hospitalized control subjects without a history of HF. Gut flora and plasma microbiome-related metabolites were evaluated by amplicon sequencing of the bacterial 16S ribosomal RNA gene and capillary electrophoresis time-of-flight mass spectrometry, respectively. HF patients were evaluated in both the Decomp and Comp phases during hospitalization. The phylum Actinobacteria was enriched in HF patients compared with control subjects. At the genus level, Bifiodobacterium was abundant while Megamonas was depleted in HF patients. Meanwhile, plasma concentration of trimethylamine N-oxide (TMAO), a gut microbiome-derived metabolite, was increased in HF patients (Decomp HF vs. control, P=0.003; Comp HF vs. control, P=0.004). A correlation analysis revealed positive correlations between the abundance of the genus Escherichia/Shigella and levels of TMAO and indoxyl sulfate (IS, a microbe-dependent uremic toxin) in Comp HF (TMAO: r=0.62, P=0.002; IS: r=0.63, P=0.002). Escherichia/Shigella was more abundant in Decomp than in Comp HF (P=0.030).

    Conclusions

    Our results suggest that gut microbiome composition and microbiome-related metabolites are altered in HF patients.
    Nov. 2018, Circulation journal : official journal of the Japanese Circulation Society
    Scientific journal

  • Tomohiro Hayashi
    BACKGROUND:It is increasingly recognized that gut microbiota play a pivotal role in the development of atherosclerotic cardiovascular disease. Previously, we have reported that the abundance of genus Bacteroides is lower in patients with coronary artery disease (CAD) than in patients without CAD with coronary risk factors or in healthy volunteers. However, it remains unclear which and how specific gut bacteria contribute to the progression of atherosclerosis. METHODS:We recruited patients with CAD patients and controls without CAD with coronary risk factors. We then compared gut microbial composition using 16S ribosomal RNA gene sequencing in fecal samples to detect species with differential abundance between 2 groups. Subsequently, we used atherosclerosis-prone mice to study the mechanisms underlying the relationship between such species and atherosclerosis. RESULTS:Human fecal 16S ribosomal RNA gene sequencing revealed a significantly lower abundance of Bacteroides vulgatus and Bacteroides dorei in patients with CAD. This significant differential abundance was confirmed by quantitative polymerase chain reaction. Gavage with live B. vulgatus and B. dorei attenuated atherosclerotic lesion formation in atherosclerosis-prone mice, markedly ameliorating endotoxemia followed by decreasing gut microbial lipopolysaccharide production, effectively suppressing proinflammatory immune responses. Furthermore, fecal lipopolysaccharide levels in patients with CAD were significantly higher and negatively correlated with the abundance of B. vulgatus and B. dorei. CONCLUSIONS:Our translational research findings identify a previously unknown link between specific gut bacteria and atherosclerosis. Treatment with live B. vulgatus and B. dorei may help prevent CAD. CLINICAL TRIAL REGISTRATION:URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018051 . Unique identifier: UMIN000015703.
    Nov. 2018, Circulation, 138(22) (22), 2486 - 2498, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Aug. 2018, Circulation journal : official journal of the Japanese Circulation Society, 82(10) (10), 2470 - 2471, English, Domestic magazine
    Scientific journal

  • Tomohiro Hayashi

    Background

    A recent study showed that both glycosylation of pro-B-type natriuretic peptide (BNP) and the proBNP/total BNP ratio are decreased in acute decompensated heart failure (ADHF). However, the following points regarding the proBNP/total BNP ratio have not been determined in patients with ADHF: 1) the relationship with the severity of ADHF, 2) the changes in the ratio during treatment, and 3) the relationship with cyclic guanosine monophosphate (cGMP)-generating activity.

    Methods

    Plasma proBNP and total BNP (proBNP+mature BNP) were measured in patients with ADHF (n=154). Measurement was performed on admission, 3 and 7days after admission, and before discharge using recently developed sandwich chemiluminescence enzyme immunoassays. The percent proBNP was calculated as: (proBNP/total BNP)×100.

    Results

    On admission, %proBNP was higher in patients with severe ADHF than in patients with mild ADHF (median: 61.7% vs. 56.2%, respectively; p<0.01), while the plasma cGMP/total BNP ratio, an index of the biological activity of BNP, was lower (p<0.001). In patients with severe ADHF, the higher %proBNP and lower cGMP/total BNP ratio were unchanged during hospitalization, whereas %proBNP increased gradually in patients with mild ADHF and the cGMP/total BNP ratio also increased at 3days after admission.

    Conclusion

    These findings suggest that in patients with mild ADHF, compensation for heart failure occurs via increased proBNP processing, leading to increase of mature BNP and activation of the BNP/cGMP cascade. In contrast, this compensatory mechanism may be impaired in patients with severe ADHF and a vicious cycle can potentially occur.
    May 2018, International journal of cardiology, 258, 165 - 171, English, International magazine
    Scientific journal

  • Tomohiro Hayashi
    Apr. 2018, Circulation journal : official journal of the Japanese Circulation Society, 82(6) (6), 1507 - 1509, English, Domestic magazine
    Scientific journal

  • Tomohiro Hayashi

    Objective

    This retrospective cohort study was performed to examine the association between serum amiodarone (AMD) and N-desethylamiodarone (DEA) concentrations and the development of thyroid dysfunction.

    Methods

    Patients treated with AMD from January 2012 to April 2016 were identified from the computerized hospital information system database at the National Cerebral and Cardiovascular Center. Only patients whose serum AMD and DEA concentrations had been determined at least once were included in the study.

    Results

    A total of 377 patients were enrolled. Consequently, 54 (14.3%) and 60 (15.9%) patients who developed AMD-induced thyrotoxicosis and hypothyroidism were included. The mean DEA/AMD ratio during the pre-index period in the thyrotoxicosis group (0.86 ± 0.24) was significantly higher than in the hypothyroidism (0.68 ± 0.27) and euthyroidism (0.78 ± 0.30; p < 0.0001) groups. In addition, the mean DEA/AMD ratio during the post-index period in the thyrotoxicosis group (1.05 ± 0.40) was significantly higher than in the hypothyroidism (0.81 ± 0.24) and euthyroidism (0.88 ± 0.22; p < 0.0001) groups. A persistently higher DEA/AMD ratio was observed throughout the study period in the thyrotoxicosis group. In addition, good correlations between the DEA/AMD ratio and the levels of free thyroxine, free triiodothyronine levels, and log (thyroid-stimulating hormone) were observed in the thyrotoxicosis and euthyroidism groups.

    Conclusion

    Patients with AMD-induced thyrotoxicosis had an increased DEA/AMD ratio and patients with AMD-induced hypothyroidism had a decreased DEA/AMD ratio before the development of thyroid dysfunction. The DEA/AMD ratio may be a predictive marker for AMD-induced thyroid dysfunction.
    Jan. 2018, Clinical drug investigation, 38(1) (1), 39 - 48, English, International magazine
    Scientific journal

  • Tomohiro Hayashi, Naoto Sasaki, Tomoya Yamashita, Taiji Mizoguchi, Takuo Emoto, Hilman Zulkifli Amin, Keiko Yodoi, Takuya Matsumoto, Kazuyuki Kasahara, Naofumi Yoshida, Tokiko Tabata, Naoki Kitano, Atsushi Fukunaga, Chikako Nishigori, Yoshiyuki Rikitake, Ken-Ichi Hirata
    BACKGROUND: Pathogenic immune responses are known to play an important role in abdominal aortic aneurysm (AAA) development. Ultraviolet B (UVB) irradiation has been demonstrated to have therapeutic potential not only for cutaneous diseases but also for systemic inflammatory diseases in mice by suppressing immunoinflammatory responses. We investigated the effect of UVB irradiation on experimental AAA. METHODS AND RESULTS: We used an angiotensin II-induced AAA model in apolipoprotein E-deficient mice fed a high-cholesterol diet. Mice aged 10 weeks were irradiated with 5 kJ/m2 UVB once weekly for 6 weeks (UVB-irradiated, n=38; nonirradiated, n=42) and were euthanized for evaluation of AAA formation at 16 weeks. Overall, 93% of angiotensin II-infused mice developed AAA, with 60% mortality possibly because of aneurysm rupture. UVB irradiation significantly decreased the incidence (66%) and mortality (29%) of AAA (P=0.004 and P=0.006, respectively). UVB-irradiated mice had significantly smaller diameter AAA (P=0.008) and fewer inflammatory cells in the aortic aneurysm tissue than nonirradiated mice, along with systemic expansion of CD4+Foxp3+ regulatory T cells and decreased effector CD4+CD44highCD62Llow T cells in para-aortic lymph nodes. Genetic depletion of regulatory T cells abrogated these beneficial effects of UVB treatment, demonstrating a critical role of regulatory T cells. CONCLUSIONS: Our data suggest that UVB-dependent expansion of regulatory T cells has beneficial effects on experimental AAA and may provide a novel strategy for the treatment of AAA.
    Aug. 2017, Journal of the American Heart Association, 6(9) (9), English, International magazine
    Scientific journal

  • Naofumi Yoshida, Hiroyuki Yamamoto, Toshiro Shinke, Hiromasa Otake, Masaru Kuroda, Daisuke Terashita, Hachidai Takahashi, Kazuhiko Sakaguchi, Yushi Hirota, Takuo Emoto, Hilman Zulkifli Amin, Taiji Mizoguchi, Tomohiro Hayashi, Naoto Sasaki, Tomoya Yamashita, Wataru Ogawa, Ken-Ichi Hirata
    BACKGROUND: Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14++CD16+ monocytes on plaque vulnerability, as assessed by virtual histology intravascular ultrasound (VH-IVUS), as well as their relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). METHODS: Fifty-one patients with asymptomatic CAD, who were undergoing lipid-lowering therapy and underwent VH-IVUS evaluation for angiographically mild to moderate lesions, were enrolled in the study. Standard VH-IVUS parameters, including the percentage volume of the necrotic core (%NC) within the plaque and the presence of a virtual histology thin-cap fibroatheroma (VH-TCFA), were then evaluated. Additionally, monocyte subsets were assessed by flow cytometry, and daily glucose fluctuations were analyzed by measuring the mean amplitude of glycemic excursion (MAGE). RESULTS: Among 82 plaques from 22 diabetes mellitus (DM) patients and 29 non-DM patients, 15 VH-TCFAs were identified. CD14++CD16+ monocyte counts significantly correlated with both  %NC and the presence of VH-TCFA (%NC: r = 0.339, p = 0.002; VH-TCFA: p = 0.003). Multivariate logistic regression analysis revealed that CD14++CD16+ monocyte counts were independently associated with VH-TCFA (odds ratio = 1.029, p = 0.004). Furthermore, CD14++CD16+ monocyte counts were significantly correlated with the MAGE score in the non-DM patients (r = 0.544, p = 0.005). CONCLUSIONS: CD14++CD16+ monocyte levels are associated with coronary plaque vulnerability and can serve as a biomarker for VH-TCFA in patients with CAD undergoing lipid-lowering therapy. In patients without DM, glucose fluctuations may alter the balance of monocyte subsets. Trial registration UMIN Registry number: UMIN000021228.
    Aug. 2017, Cardiovascular diabetology, 16(1) (1), 96 - 96, English, International magazine
    Scientific journal

  • Taiji Mizoguchi, Kazuyuki Kasahara, Tomoya Yamashita, Naoto Sasaki, Keiko Yodoi, Takuya Matsumoto, Takuo Emoto, Tomohiro Hayashi, Naoki Kitano, Naofumi Yoshida, Hilman Zulkifli Amin, Ken-ichi Hirata
    Jun. 2017, HEART AND VESSELS, 32(6) (6), 768 - 776, English
    Scientific journal

  • Tomohiro Hayashi
    Apr. 2017, European journal of clinical pharmacology, 73(8) (8), 1053 - 1054, English, International magazine
    Scientific journal

  • Kazuyuki Kasahara, Takeshi Tanoue, Tomoya Yamashita, Keiko Yodoi, Takuya Matsumoto, Takuo Emoto, Taiji Mizoguchi, Tomohiro Hayashi, Naoki Kitano, Naoto Sasaki, Koji Atarashi, Kenya Honda, Ken-ichi Hirata
    Mar. 2017, JOURNAL OF LIPID RESEARCH, 58(3) (3), 519 - 528, English
    Scientific journal

  • Mikie Yamato, Kyoichi Wada, Mai Fujimoto, Kouichi Hosomi, Tomohiro Hayashi, Akira Oita, Mitsutaka Takada
    PURPOSE: We used a retrospective data mining approach to explore the association between serum amiodarone (AMD) and N-desethylamiodarone (DEA) concentrations and thyroid-related hormone levels. METHODS: Laboratory data sets from January 2012 to April 2016 were extracted from the computerized hospital information system database at the National Cerebral and Cardiovascular Center (NCVC). Data sets that contained serum AMD and DEA concentrations and thyroid function tests, including thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3), were analyzed. RESULTS: A total of 1831 clinical laboratory data sets from 330 patients were analyzed. Data sets were classified into five groups (euthyroidism, hyperthyroidism, subclinical hyperthyroidism, hypothyroidism, and subclinical hypothyroidism) based on the definition of thyroid function in our hospital. Most abnormal levels of thyroid hormones were observed within the therapeutic range of serum AMD and DEA concentrations. The mean DEA/AMD ratio in the hyperthyroidism group was significantly higher than that in the euthyroidism group (0.95 ± 0.42 vs. 0.87 ± 0.28, p = 0.0209), and the mean DEA/AMD ratio in the hypothyroidism group was significantly lower than that in the euthyroidism group (0.77 ± 0.26 vs. 0.87 ± 0.28, p = 0.0038). The suppressed TSH group (0.98 ± 0.41 vs. 0.87 ± 0.28, p < 0.001) and the elevated FT4 level group (0.90 ± 0.33 vs. 0.84 ± 0.27, p = 0.0037) showed significantly higher DEA/AMD ratios compared with normal level groups. The elevated TSH group showed a significantly lower DEA/AMD ratio compared with the normal group (0.81 ± 0.25 vs. 0.87 ± 0.28, p < 0.0001). CONCLUSIONS: High and low DEA/AMD ratios were associated with AMD-induced hyperthyroidism and hypothyroidism, respectively. The DEA/AMD ratio may be a predictive marker for AMD-induced thyroid dysfunction.
    Mar. 2017, European journal of clinical pharmacology, 73(3) (3), 289 - 296, English, International magazine
    Scientific journal

  • Takuo Emoto, Tomoya Yamashita, Toshio Kobayashi, Naoto Sasaki, Yushi Hirota, Tomohiro Hayashi, Anna So, Kazuyuki Kasahara, Keiko Yodoi, Takuya Matsumoto, Taiji Mizoguchi, Wataru Ogawa, Ken-Ichi Hirata
    The association between atherosclerosis and gut microbiota has been attracting increased attention. We previously demonstrated a possible link between gut microbiota and coronary artery disease. Our aim of this study was to clarify the gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism (T-RFLP). This study included 39 coronary artery disease (CAD) patients and 30 age- and sex- matched no-CAD controls (Ctrls) with coronary risk factors. Bacterial DNA was extracted from their fecal samples and analyzed by T-RFLP and data mining analysis using the classification and regression algorithm. Five additional CAD patients were newly recruited to confirm the reliability of this analysis. Data mining analysis could divide the composition of gut microbiota into 2 characteristic nodes. The CAD group was classified into 4 CAD pattern nodes (35/39 = 90 %), while the Ctrl group was classified into 3 Ctrl pattern nodes (28/30 = 93 %). Five additional CAD samples were applied to the same dividing model, which could validate the accuracy to predict the risk of CAD by data mining analysis. We could demonstrate that operational taxonomic unit 853 (OTU853), OTU657, and OTU990 were determined important both by the data mining method and by the usual statistical comparison. We classified the gut microbiota profiles in coronary artery disease patients using data mining analysis of T-RFLP data and demonstrated the possibility that gut microbiota is a diagnostic marker of suffering from CAD.
    Jan. 2017, Heart and vessels, 32(1) (1), 39 - 46, English, Domestic magazine
    Scientific journal

  • Naoto Sasaki, Tomoya Yamashita, Kazuyuki Kasahara, Atsushi Fukunaga, Tomoyuki Yamaguchi, Takuo Emoto, Keiko Yodoi, Takuya Matsumoto, Kenji Nakajima, Tomoyuki Kita, Masafumi Takeda, Taiji Mizoguchi, Tomohiro Hayashi, Yoshihiro Sasaki, Mayumi Hatakeyama, Kumiko Taguchi, Ken Washio, Shimon Sakaguchi, Bernard Malissen, Chikako Nishigori, Ken-Ichi Hirata
    OBJECTIVE: UVB irradiation is an established treatment for immunoinflammatory cutaneous disorders and has been shown to suppress cutaneous and systemic inflammatory diseases through modulation of the adaptive immune response. However, it remains unknown whether UVB irradiation prevents an immunoinflammatory disease of arteries such as atherosclerosis. APPROACH AND RESULTS: Here, we show that UVB exposure inhibits the development and progression of atherosclerosis in atherosclerosis-prone mice by expanding and enhancing the functional capacity of CD4+ forkhead box P3+ regulatory T cells and regulating proatherogenic T-cell responses. Experimental studies in Langerhans cell-depleted mice revealed that epidermal Langerhans cells play a critical role in UVB-dependent induction of CD4+ forkhead box P3+ regulatory T cells, suppression of proatherogenic T-cell responses, and prevention of atherosclerotic plaque development. CONCLUSIONS: Our findings suggest the skin immune system as a novel therapeutic target for atherosclerosis and provide a novel strategy for the treatment and prevention of atherosclerosis.
    Jan. 2017, Arteriosclerosis, thrombosis, and vascular biology, 37(1) (1), 66 - 74, English, International magazine
    Scientific journal

  • Risk factors for amiodarone-induced thyroid dysfunction in Japan.
    Sayoko Kinoshita, Tomohiro Hayashi, Kyoichi Wada, Mikie Yamato, Takeshi Kuwahara, Toshihisa Anzai, Mai Fujimoto, Kouichi Hosomi, Mitsutaka Takada
    BACKGROUND: Amiodarone is associated with a number of significant adverse effects, including elevated transaminase levels, pulmonary fibrosis, arrhythmia, and thyroid dysfunction. Although thyroid dysfunction is considered to be a common and potentially serious adverse effect of amiodarone therapy, the exact pathogenesis remains unknown because of its complex manifestations. Therefore, the prevalence of, and risk factors for, amiodarone-induced thyroid dysfunction in Japanese patients were investigated in the present study. METHODS: A retrospective analysis of patients treated with amiodarone between January 2012 and December 2013 was performed. A total of 317 patients with euthyroidism, or subclinical hyperthyroidism or hypothyroidism, were enrolled in this study. RESULTS: After being treated with amiodarone, 30 (9.5%) and 60 patients (18.9%) developed amiodarone-induced hyperthyroidism and amiodarone-induced hypothyroidism, respectively. Ten (33.3%) patients with amiodarone-induced hyperthyroidism and 40 (66.6%) with amiodarone-induced hypothyroidism were diagnosed within two years of the initiation of amiodarone therapy. Dilated cardiomyopathy (DCM) [Adjusted odds ratio (OR) 3.30 (95% confidence interval (CI): 1.26-8.90)], and cardiac sarcoidosis [Adjusted OR 6.47 (95% CI: 1.60-25.77)] were identified as predictors of amiodarone-induced hyperthyroidism. The baseline free thyroxine (T4) level [Adjusted OR 0.13 (95% CI: 0.03-0.68)], and thyroid-stimulating hormone (TSH) level [Adjusted OR1.47 (95% CI: 1.26-1.74)] were identified as predictors of amiodarone-induced hypothyroidism. CONCLUSION: DCM and cardiac sarcoidosis were identified as risk factors for amiodarone-induced hyperthyroidism. Risk factors for amiodarone-induced hypothyroidism included higher baseline TSH level and lower baseline free T4 level, suggesting that subclinical hypothyroidism may be a potential risk factor for the development of amiodarone-induced hypothyroidism.
    Dec. 2016, Journal of arrhythmia, 32(6) (6), 474 - 480, English, Domestic magazine
    Scientific journal

  • Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure.
    Tomohiro Hayashi, Takuya Hasegawa, Hideaki Kanzaki, Akira Funada, Makoto Amaki, Hiroyuki Takahama, Takahiro Ohara, Yasuo Sugano, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai
    AIMS: Altered thyroid hormone metabolism characterized by a low triiodothyronine (T3), so-called low-T3 syndrome, is a common finding in patients with severe systemic diseases. Additionally, subclinical thyroid dysfunction, defined as abnormal thyroid stimulating hormone (TSH) and normal thyroxine (T4), causes left ventricular dysfunction. Our objective was to identify the prevalence and prognostic impact of low-T3 syndrome and subclinical thyroid dysfunction in patients with acute decompensated heart failure (ADHF). METHODS AND RESULTS: We examined 274 ADHF patients who were not receiving thyroid medication or amiodarone on admission (70 ± 15 years, 156 male), who underwent thyroid function tests. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L; subclinical hypothyroidism as TSH of 4.5 to 19.9 mIU/L; and subclinical hyperthyroidism as TSH < 0.45 mIU/L, with normal free T4 level for the last two. Additionally, low-T3 syndrome was defined as free T3 < 4.0 pmol/L among euthyroidism subjects. On admission, 188 patients (69%) showed euthyroidism, 58 (21%) subclinical hypothyroidism, 5 (2%) subclinical hyperthyroidism, and 95 (35%) low-T3 syndrome. Cox proportional hazards models revealed that higher TSH, but not free T3 and free T4, was independently associated with composite cardiovascular events, including cardiac death and re-hospitalization for heart failure. Indeed, subclinical hypothyroidism was an independent predictor (hazard ratio: 2.31; 95% confidence interval: 1.44 to 3.67; P < 0.001), whereas low-T3 syndrome and subclinical hyperthyroidism were not. CONCLUSIONS: Subclinical hypothyroidism on admission was an independent predictor of adverse cardiovascular outcomes in ADHF patients, suggesting a possible interaction between thyroid dysfunction and the pathophysiology of ADHF.
    Sep. 2016, ESC heart failure, 3(3) (3), 168 - 176, English, International magazine
    Scientific journal

  • Takuo Emoto, Tomoya Yamashita, Naoto Sasaki, Yushi Hirota, Tomohiro Hayashi, Anna So, Kazuyuki Kasahara, Keiko Yodoi, Takuya Matsumoto, Taiji Mizoguchi, Wataru Ogawa, Ken-Ichi Hirata
    AIM: Recent studies have suggested that metabolic disorders such as obesity and type 2 diabetes are associated with gut microbiota. The association between atherosclerosis and gut microbiota has also been attracting increased attention. Our aim was to specify a characteristic trend of gut microbiota in coronary artery disease (CAD). METHODS: This study included 39 CAD patients, 30 age- and sex-matched no-CAD controls (Ctrls) with coronary risk factors and 50 healthy volunteers (HVs) without coronary risk factors. Bacterial DNA was extracted from their fecal samples and analyzed by terminal restriction fragment length polymorphism. RESULTS: A characteristic change of gut microbiota was observed in CAD patients, where the order Lactobacillales was increased (CAD, Ctrl vs. HV; 13.6%±12.0%, 6.2%±7.7% vs. 4.1%±5.9%; p＜0.001) and the phylum Bacteroidetes (Bacteroides＋Prevotella) was decreased (CAD, Ctrl vs. HV;35.5%±11.6%, 43.9%±11.2% vs. 47.4%±11.5%; p＜0.001). The CAD group was over-represented in enterotype "others" (III), compared with the Ctrl or HV group (p＜0.001, chi-squared test), although we could not deny the possibility that some drugs affect the gut flora types. CONCLUSIONS: Although this study had some limitations, we demonstrated that the incidence of CAD was linked with an alteration of gut microbiota. A prospective study is desired to clarify a causal relationship between CAD and gut microbiota.
    Aug. 2016, Journal of atherosclerosis and thrombosis, 23(8) (8), 908 - 21, English, Domestic magazine
    Scientific journal

  • Chiaki Nagai-Okatani, Kenji Kangawa, Seiji Takashio, Hiroyuki Takahama, Tomohiro Hayashi, Toshihisa Anzai, Naoto Minamino
    Jul. 2016, JOURNAL OF APPLIED LABORATORY MEDICINE, 1(1) (1), 47 - 59, English
    Scientific journal

  • Takuya Matsumoto, Naoto Sasaki, Tomoya Yamashita, Takuo Emoto, Kazuyuki Kasahara, Taiji Mizoguchi, Tomohiro Hayashi, Keiko Yodoi, Naoki Kitano, Takashi Saito, Tomoyuki Yamaguchi, Ken-Ichi Hirata
    OBJECTIVE: Although T-cell-mediated chronic inflammation contributes to atherosclerosis development, the role of a negative regulatory molecule cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in atherosclerosis is poorly understood. We investigated the effects of CTLA-4 overexpression on atherosclerosis in apolipoprotein E-deficient (Apoe(-/-)) mice. APPROACH AND RESULTS: We generated CTLA-4 transgenic (CTLA-4-Tg)/Apoe(-/-) mice that display constitutive cell surface and intracellular expression of CTLA-4 in T cells and assessed atherosclerosis at age 16 weeks. CTLA-4 overexpression significantly reduced atherosclerotic lesion formation and intraplaque accumulation of macrophage and CD4(+) T cells in the aortic root compared with controls. CTLA-4-Tg/Apoe(-/-) mice showed decreased numbers of effector CD4(+) T cells and decreased expression of costimulatory molecules CD80 and CD86, ligands for CTLA-4, and a costimulatory molecule CD28, on CD11c(+) dendritic cells compared with controls. Consistent with in vivo findings, in vitro experiments revealed that CD4(+) T cells from CTLA-4-Tg/Apoe(-/-) mice showed decreased proliferative capacity and proinflammatory cytokine production, downregulated CD80 expression on CD11c(+) dendritic cells, and suppressed the proliferation of other T cells by limiting the costimulatory pathway. Moreover, CD11c(+) dendritic cells from CTLA-4-Tg/Apoe(-/-) mice showed reduced proliferative activity of T cells in vitro, suggesting the suppression of dendritic cell maturation in vivo. CONCLUSIONS: CTLA-4 regulates atherosclerosis by suppressing proatherogenic immune responses and could be an attractive therapeutic target for atherosclerosis.
    Jun. 2016, Arteriosclerosis, thrombosis, and vascular biology, 36(6) (6), 1141 - 51, English, International magazine
    Scientific journal

  • Tomohiro Hayashi, Takakazu Hayashi, Toshimi Hayashi, Kei Kamide
    N-terminal proB-type natriuretic peptide (NT-proBNP) is known as a marker of heart failure (HF). NT-proBNP is also elevated in a patient with atrial fibrillation (AF). In this case report, serial assays of NT-proBNP were performed in AF attack without HF. We found the positive association between the level of NT-proBNP and duration of AF attack. This case suggested that secretion of NT-proBNP from left atrium might be abundant in the case of paroxysmal AF (PAF) or PAF might lead to increasing left ventricle stress in a time-dependent manner. Moreover, it is suggested that the measurement of NT-proBNP levels considering the elapsed time after the onset of PAF would be useful. .
    Jan. 2016, Journal of cardiology cases, 13(1) (1), 14 - 16, English, Domestic magazine
    Scientific journal

  • Seiji Takashi, Seigo Sugiyama, Megumi Yamamuro, Hiroyuki Takahama, Tomohiro Hayashi, Yasuo Sugano, Yasuhiro Izumiya, Seiji Hokimoto, Naoto Minamino, Satoshi Yasuda, Toshihisa Anzai, Hisao Ogawa
    Jul. 2015, AMERICAN JOURNAL OF CARDIOLOGY, 116(2) (2), 243 - 249, English
    Scientific journal

  • Tomohiro Hayashi, Jun-ichi Kotani, Hatsue Ishibashi-Ueda, Satoshi Yasuda
    A 60-year-old man who had received repeated angioplasty for silent ischemia was suspected to have restenosis based on radioisotope imaging (exercise-RI) findings 6 months after everolimus-eluting stent (EES) implantation (3.5 × 28, 3.5 × 28, 3.0 × 18 mm). The stents had been implanted for chronic total occlusion of the right coronary artery (RCA), and the patient was on continuous dual antiplatelet therapy. Diagnostic angiography demonstrated in-stent restenosis in the proximal RCA, which was treated by optical coherence tomography (OCT)-guided cutting balloon angioplasty with distal protection. OCT findings of the stenotic segment before angioplasty showed that the lesion had complex features. The lesion was successfully dilated, and whitish material obtained by a distal protection device was composed of fibrin thrombi with neutrophils and small pieces of mature fibrocellular neointima. The mechanisms and patterns of restenosis after EES placement have not been well clarified. This case may reflect a restenosis pattern (i.e., asymptomatic, focal, and thrombi-related) in the era of the newer generation of drug-eluting stents.
    Mar. 2014, Heart and vessels, 29(2) (2), 273 - 7, English, Domestic magazine
    Scientific journal

  • A successful case of percutaneous transluminal septal myocardial ablation for mitral regurgitation that emerged following mitral valve repair surgery.
    Tomohiro Hayashi, Makoto Amaki, Hideaki Kanzaki, Akira Funada, Yasuo Sugano, Takahiro Ohara, Hiroyuki Takahama, Takuya Hasegawa, Masafumi Kitakaze, Toshihisa Anzai
    A 70-year-old man complaining of exertional dyspnea was referred to our hospital for recurrence of mitral regurgitation (MR) after mitral valve repair. Echocardiography revealed the presence of a bulging subaortic septum with flow acceleration in the left ventricular outflow tract (LVOT) and systolic anterior motion of the mitral valve with moderate MR, consistent with LVOT obstruction. Since medical therapy was not sufficiently effective, we performed percutaneous transluminal septal myocardial ablation (PTSMA). After the procedure, the MR resolved, with a reduced LVOT pressure gradient. The patient's symptoms improved. PTSMA was effective for the treatment of MR that emerged after mitral valve repair.
    2013, Internal medicine (Tokyo, Japan), 52(24) (24), 2765 - 9, English, Domestic magazine
    Scientific journal

■ MISC
  • 山下 智也, 林 友鴻, 江本 拓央
    医歯薬出版(株), Nov. 2025, 医学のあゆみ, 295(9) (9), 802 - 806, Japanese

  • B細胞除去療法後の免疫不全状態で，遷延・再燃したCOVID-19肺炎に対してエンシトレルビルを含む集学的治療が著効した1例
    灰野義隆, 林友鴻, 藥師神公和, 西崎朗, 見坂恒明
    Apr. 2025, 日本内科学会ことはじめ 2025

  • 長時間の正座姿勢により下腿の蜂窩織炎,横紋筋融解症を来した1例
    小林崇人, 林友鴻, 見坂恒明
    (一社)日本プライマリ・ケア連合学会, 2024, 日本プライマリ・ケア連合学会学術大会(Web), 15th, 369 - 369, Japanese

  • 自殺企図でOTC医薬品のジフェンヒドラミンを過量内服した1例
    松井算, 林友鴻, 見坂恒明
    (一社)日本プライマリ・ケア連合学会, 2024, 日本プライマリ・ケア連合学会学術大会(Web), 15th, 354 - 354, Japanese

  • Study for attitude to community medicine of residents comparing face-to-face and online lectures.
    見坂恒明, 林友鴻, 水谷直也, 隈部綾子, 岡山雅信
    (一社)日本医学教育学会, 2024, 医学教育, 55(Suppl.) (Suppl.), 254 - 254, Japanese

  • 丹波圏域初の日本紅斑熱の1例
    高田京加, 林友鴻, 見坂恒明
    (一社)日本プライマリ・ケア連合学会, 2024, 日本プライマリ・ケア連合学会学術大会(Web), 15th, 416 - 416, Japanese

  • Single Cell RNA Sequencing Reveals a Distinct Immune Landscape in the Left Atria in Atrial Fibrillation Patients
    鈴木雄也, 江本拓央, 佐藤俊輔, 遠藤広美, 井上大志, 林友鴻, 仁田英里子, 小西弘樹, 木内邦彦, 高見充, 高見充, 谷口将之, 古屋敷智之, 古屋敷智之, 仁田亮, 仁田亮, 山下智也, 山下智也, 平田健一, 福沢公二, 福沢公二
    (一社)日本心臓病学会, 2023, 日本心臓病学会学術集会(Web), 71st, YIA - 3, English

  • 山下 智也, 林 友鴻, 平田 健一
    (株)メジカルビュー社, Jun. 2021, Heart View, 25(6) (6), 520 - 525, Japanese

  • Heart failure and gut microbiota
    山下智也, 林友鴻, 平田健一
    2021, Heart View, 25(6) (6)

  • U40世代が描く心不全診療の現状と未来-基礎研究を識り,臨床を素心深考する-臓器関連 臨床編 腸管が心不全に及ぼす影響と病態はどのようなものですか?
    林友鴻, 山下智也, 平田健一
    2020, 循環器ジャーナル, 68(1) (1)

  • Alteration of Gut Microbiota Could be a Novel Therapeutic Strategy for Preventing Atherosclerotic Cardiovascular Diseases
    山下智也, 吉田尚史, 林友鴻, 田畑論子, 江本拓央, 平田健一
    (株)ライフ・サイエンス, 2020, Progress in Medicine, 40(3) (3), 223 - 229, Japanese

  • Superior Predictability of proANP Level on Admission for Clinical Outcomes in Acute Heart Failure Patients: Comparison with proBNP and BNP(和訳中)
    高濱 博幸, 高潮 征爾, 錦見 俊雄, 林 友鴻, 中川 靖章, 天野 雅史, 濱谷 康弘, 岡田 厚, 天木 誠, 長谷川 拓也, 神崎 秀明, 安田 聡, 安斉 俊久, 南野 直人, 泉 知里
    (一社)日本循環器学会, Mar. 2019, 日本循環器学会学術集会抄録集, 83回, PJ034 - 6, English

  • 循環器疾患と腸内細菌叢
    山下智也, 吉田尚史, 江本拓央, 林友鴻, 田畑論子, 平田健一
    (一財)医薬品医療機器レギュラトリーサイエンス財団, 2019, 医薬品医療機器レギュラトリーサイエンス, 50(9) (9), 504 - 512, Japanese

  • Bacteroides vulgatusとBacteroides doreiは腸内細菌のLPS産生を減少させ動脈硬化を抑制する
    吉田尚史, 山下智也, 江本拓央, 渡邊日佳流, 林友鴻, 田畑論子, 山田拓司, 平田健一
    (一社)日本動脈硬化学会, 2019, 日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 51st, YIA - 1, Japanese

  • Superior Predictability of proANP Level on Admission for Clinical Outcomes in Acute Heart Failure Patients: Comparison with proBNP and BNP
    高濱博幸, 高潮征爾, 錦見俊雄, 林友鴻, 中川靖章, 天野雅史, 濱谷康弘, 岡田厚, 天木誠, 長谷川拓也, 神崎秀明, 安田聡, 安斉俊久, 南野直人, 泉知里
    (一社)日本循環器学会, 2019, 日本循環器学会学術集会(Web), 83rd, PJ034 - 6, English

  • Bacteroides vulgatusとBacteroides doreiは腸内細菌のリポ多糖類産生を調節することによってアテローム性動脈硬化症から保護する(Bacteroides Vulgatus and Bacteroides Dorei protect Against Atherosclerosis by Regulating Gut Microbial Lipopolysaccharide Production)
    吉田 尚史, 山下 智也, 江本 拓央, 渡邊 日佳流, 林 友鴻, 田畑 論子, 佐々木 直人, 山田 拓司, 平田 健一
    (一社)日本心臓病学会, Sep. 2018, 日本心臓病学会学術集会抄録, 66回, YIA - 4, English

  • 紫外線B波照射はCD4陽性Foxp3陽性制御性T細胞を増幅し,アンギオテンシンII誘導性マウス大動脈瘤の形成を抑制する
    林友鴻, 佐々木直人, 山下智也, 溝口泰司, 江本拓央, AMIN Hilman Zulkifli, 淀井(眞弓)景子, 松本卓也, 笠原和之, 吉田尚史, 田畑論子, 北野尚樹, 福永淳, 錦織千佳子, 力武良行, 平田健一
    (一社)日本動脈硬化学会, 2018, 日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 50th, 262 - 262, Japanese

  • Bacteroidesは糞便LPS値を低下させる事で動脈硬化を抑制する
    吉田尚史, 山下智也, 江本拓央, 渡邊日佳流, 林友鴻, 田畑論子, 小澤元希, 佐々木直人, 山田拓司, 平田健一
    (一社)日本動脈硬化学会, 2018, 日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 50th, 287 - 287, Japanese

  • 腸管免疫・腸内細菌叢と冠動脈疾患
    山下智也, 吉田尚史, 林友鴻, 江本拓央, 溝口泰司, 笠原和之, 佐々木直人, 平田健一
    (有)科学評論社, 2018, 循環器内科, 84(5) (5), 584 - 590, Japanese

  • 冠動脈疾患と心不全における心臓腸管連関
    山下智也, 林友鴻, 平田健一
    2018, 日本心不全学会学術集会プログラム・抄録集, 22nd

  • 心房細動・心不全と腸内細菌
    林友鴻, 山下智也, 平田健一
    (有)科学評論社, 2018, 循環器内科, 84(1) (1), 86 - 92, Japanese

  • Bacteroidesは腸内細菌のLPS産生を制御し動脈硬化を抑制する
    吉田尚史, 山下智也, 江本拓央, 渡邊日佳流, 林友鴻, 田畑論子, 小澤元希, 山田拓司, 平田健一
    (公財)腸内細菌学会, 2018, 腸内細菌学雑誌, 32(2) (2), 96 - 96, Japanese

  • 第82回日本循環器学会学術集会 1.心不全の革新的予防戦略 心不全患者における腸内フローラおよび腸内細菌由来代謝産物の変化
    林友鴻, 山下智也, 平田健一
    (一社)日本循環器学会, 2018, 循環器専門医, 27, 3 - 8, Japanese

  • 心不全の分子機序 多臓器連関の基礎研究 腸内細菌と心不全
    山下智也, 林友鴻, 平田健一
    (株)日本臨床社, 2018, 日本臨床, 76(増刊9 心不全(上)) (増刊9 心不全(上)), 358 - 362, Japanese

  • Gut Microbiota and Their Relevant Metabolites could be Novel Biomarkers and Innovative Therapeutic Targets of Chronic Heart Failure
    林友鴻, 山下智也, 平田健一
    (一社)日本循環器学会, 2018, 日本循環器学会学術集会(Web), 82nd, PL8 - 5, English

  • ProBNP Ratio to Total BNP Predicts Future Cardiac Reverse Remodeling in Acute Heart Failure Patients with Reduced Ejection Fraction
    高濱博幸, 高潮征爾, 錦見俊雄, 林友鴻, 岡谷千晶, 中川靖章, 濱谷康弘, 岡田厚, 天木誠, 長谷川拓也, 菅野康夫, 神崎秀明, 安田聡, 寒川賢治, 南野直人, 安斉俊久
    (一社)日本循環器学会, 2018, 日本循環器学会学術集会(Web), 82nd, OJ20 - 2, English

  • Association of Ratio of proBNP to Total BNP with Heart Failure Severity: A Novel Compensatory Mechanism for Acute Heart Failure
    高濱博幸, 高潮征爾, 錦見俊雄, 林友鴻, 岡谷千晶, 中川靖章, 天木誠, 大原貴裕, 長谷川拓也, 菅野康夫, 神崎秀明, 安田聡, 寒川賢治, 南野直人, 安斉俊久
    (一社)日本循環器学会, 2018, 日本循環器学会学術集会(Web), 82nd, PJ042 - 1, English

  • 心房性ナトリウム利尿ペプチドの3種の内在分子型の測定意義
    南野 直人, 永井 千晶, 谷, 高潮 征爾, 高濱 博幸, 林 友鴻, 安斉 俊久, 寒川 賢治
    (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 894 - 894, Japanese

  • 紫外線照射による動脈硬化抑制効果の検討
    佐々木直人, 林友鴻, 福永淳, 錦織千佳子, 山下智也, 平田健一, 力武良行
    2017, 日本光医学・光生物学会, 39th

  • 血清アミオダロン及び代謝物濃度と甲状腺機能異常との関連
    大和幹枝, 和田恭一, 林友鴻, 寺川伸江, 川端一功, 藤本麻依, 細見光一, 老田章, 高田充隆
    (一社)日本心臓病学会, 2017, 日本心臓病学会学術集会(Web), 65th, O - 145, Japanese

  • 冠動脈疾患と心不全における腸内細菌の役割
    林友鴻, 山下智也, 平田健一
    2017, 日本心血管内分泌代謝学会学術総会プログラム及び抄録集, 21st

  • 腸内細菌関連代謝産物と心不全との関係
    田畑論子, 林友鴻, 山下智也, 江本拓央, 吉田尚史, 溝口泰司, 平田健一
    2017, 日本循環器学会近畿地方会(Web), 124th

  • Is There a Relationship in Molar Ratio of Circulating BNP Molecular Forms with Renal Function in Acute Heart Failure Patients?
    高濱博幸, 高潮征爾, 林友鴻, 岡谷千晶, 錦見俊雄, 中川靖章, 天木誠, 大原貴裕, 長谷川拓也, 菅野康夫, 神崎秀明, 安田聡, 寒川賢治, 南野直人, 安斉俊久
    (一社)日本循環器学会, 2017, 日本循環器学会学術集会(Web), 81st, OJ - 013, English

  • Determining Factors and Prognostic Value of Plasma gamma- Atrial Natriuretic Peptide Ratio in Patients With Heart Failure
    Seiji Takashio, Hiroyuki Takahama, Tomohiro Hayashi, Chiaki Nagai-Okatani, Toshio Nishikimi, Yasuaki Nakagawa, Makoto Amaki, Takahiro Ohara, Takuya Hasegawa, Yasuo Sugano, Hideaki Kanzaki, Satoshi Yasuda, Kenji Kangawa, Naoto Minamino, Toshihisa Anzai
    Nov. 2016, CIRCULATION, 134, English
    Summary international conference

  • Determining Factors and Prognostic Value of Plasma gamma-Atrial Natriuretic Peptide Ratio in Patients With Heart Failure
    Seiji Takashio, Hiroyuki Takahama, Tomohiro Hayashi, Chiaki Nagai-Okatani, Toshio Nishikimi, Yasuaki Nakagawa, Makoto Amaki, Takahiro Ohara, Takuya Hasegawa, Yasuo Sugano, Hideaki Kanzaki, Satoshi Yasuda, Kenji Kangawa, Naoto Minamino, Toshihisa Anzai
    Nov. 2016, CIRCULATION, 134, English
    [Refereed]
    Summary international conference

  • Serial Measurements of High Sensitivity Cardiac Troponin T Levels in Acute Decompensated Heart Failure
    Seiji Takashio, Hiroyuki Takahama, Tomohiro Hayashi, Toshihisa Anzai
    Sep. 2016, JOURNAL OF CARDIAC FAILURE, 22(9) (9), S175 - S176, English
    Summary international conference

  • Changes in the Ratio of Plasma B-Type Natriuretic Peptide Molecular Forms in Patients Hospitalized with Acute Decompensated Heart Failure
    Hiroyuki Takahama, Seiji Takashio, Tomohiro Hayashi, Naoto Minamino, Toshihisa Anzai
    Sep. 2016, JOURNAL OF CARDIAC FAILURE, 22(9) (9), S181 - S181, English
    Summary international conference

  • Relationships of B-Type Natriuretic Peptides (BNP) Measured by Conventional Assay with proBNP(1-108) and N-Terminal proBNP(1-76) in Heart Failure Patients
    Hiroyuki Takahama, Seiji Takashio, Tomohiro Hayashi, Chiaki Okatani Nagai, Toshio Nishikimi, Yasuaki Nakagawa, Yasuo Sugano, Hideaki Kanzaki, Naoto Minamino, Toshihisa Anzai
    Sep. 2016, JOURNAL OF CARDIAC FAILURE, 22(9) (9), S181 - S181, English
    Summary international conference

  • Using The Cockcroft-Gault Equation, The Creatinine Clearance (Ccr) Could Not Represent The Glomerular Filtration Rate (GER)
    林孝和, 林寿美, 林友鴻
    2016, 呼吸と循環, 64(4) (4)

  • Usefulness of Cystatin C for Estimating Glomerular Filtration Rate (GFR)
    林孝和, 林寿美, 林友鴻
    2016, 呼吸と循環, 64(9) (9)

  • アンギオテンシンII誘導性マウス大動脈瘤モデルを用いた,UVB照射による大動脈瘤抑制効果の検討
    林友鴻, 佐々木直人, 江本拓央, 溝口泰司, 吉田尚史, HILMAN Zulkifli Amin, 松本卓也, 山下智也, 平田健一
    (一社)日本動脈硬化学会, 2016, 日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 48th, 227 - 227, Japanese

  • 心房性ナトリウム利尿ペプチドの3種の内在分子型の測定意義
    南野直人, 永井(岡谷)千晶, 高潮征爾, 高濱博幸, 林友鴻, 安斉俊久, 寒川賢治
    (一社)日本内分泌学会, 2016, 日本心血管内分泌代謝学会学術総会プログラム及び抄録集, 20th(3) (3), 894 - 894, Japanese

  • 肥満時代におけるクレアチニンクリアランス(CG式)の使用は不適切
    林孝和, 林寿美, 林友鴻
    2015, 臨床検査, 59(10) (10)

  • アミオダロン誘発性甲状腺機能異常の発症率と患者背景に関する検討
    林友鴻, 木下佐昌子, 大和幹枝, 和田恭一, 桑原健, 安田聡, 安斉俊久
    (株)ライフ・サイエンス, 2015, Progress in Medicine, 35(Suppl.1) (Suppl.1), 358 - 361, Japanese

  • 心房性ナトリウム利尿ペプチドの3種内在分子型の測定法の開発とβ型分子の測定意義
    南野直人, 岡谷千晶, 高潮征爾, 高濱博幸, 林友鴻, 安斉俊久, 寒川賢治
    (一社)日本内分泌学会, 2015, 日本内分泌学会雑誌, 91(2) (2), 639 - 639, Japanese

  • ヒト心臓及び血中に存在する3種のナトリウム利尿ペプチド内在分子型の測定法の開発とその意義
    南野直人, 永井千晶, 高濱博幸, 高潮征爾, 林友鴻, 安斉俊久, 寒川賢治
    (一社)日本内分泌学会, 2015, 日本内分泌学会雑誌, 91(1) (1), 333 - 333, Japanese

  • 冠動脈疾患患者に特徴的な腸内細菌叢の変化
    江本拓央, 山下智也, 佐々木直人, 廣田勇士, 林友鴻, 宗杏奈, 笠原和之, 淀井景子, 松本卓也, 溝口泰司, 小川渉, 平田健一
    (一社)日本動脈硬化学会, 2015, 日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 47th, 266 - 266, Japanese

  • 冠動脈疾患患者に特徴的な腸内細菌叢の同定
    江本拓央, 山下智也, 佐々木直人, 林友鴻, 笠原和之, 淀井景子, 松本卓也, 溝口泰司, 平田健一
    (公財)腸内細菌学会, 2015, 腸内細菌学雑誌, 29(2) (2), 98 - 98, Japanese

  • 急性非代償性心不全患者の血漿proBNP比率の測定意義
    高潮征爾, 高濱博幸, 永井千晶, 林友鴻, 錦見俊雄, 中川靖章, 神崎秀明, 菅野康夫, 長谷川拓也, 大原貴裕, 天木誠, 安田聡, 小川久雄, 寒川賢治, 安斉俊久, 南野直人
    (一社)日本内分泌学会, 2015, 日本内分泌学会雑誌, 91(2) (2), 644 - 644, Japanese

  • Investigation of the Differential Effects of n-3 Polyunsaturated Fatty Acids, EPA and DHA, on Angiotensin II-induced Aortic Aneurysm Formation in Mice
    淀井景子, 山下智也, 河野浩之, 佐々木直人, 北智之, 笠原和之, 佐々木義浩, 松本卓也, 江本拓央, 溝口泰司, 林友鴻, 平田健一
    ライフサイエンス出版(株), 2015, 薬理と治療, 43(10) (10), 1409 - 1416, Japanese

  • 冠動脈疾患患者における腸内細菌叢の特徴
    江本拓央, 山下智也, 佐々木直人, 林友鴻, 笠原和之, 淀井景子, 松本卓也, 溝口泰司, 平田健一
    2015, 日本血管生物医学会学術集会プログラム・抄録集, 23rd

  • 急性非代償性心不全患者の入院回復期における血漿BNP分子多型の時間的変化についての検討
    高濱博幸, 高潮征爾, 南野直人, 林友鴻, 永井千晶, 錦見俊男, 中川靖章, 天木誠, 大原貴裕, 長谷川拓也, 菅野康夫, 神崎秀明, 安田聡, 小川久雄, 寒川賢治, 安斉俊久
    2015, 日本血管生物医学会学術集会プログラム・抄録集, 23rd

  • 紫外線(UVB)照射を用いた新規動脈硬化治療法の開発
    佐々木直人, 山下智也, 笠原和之, 福永淳, 山口智之, 江本拓央, 淀井景子, 松本卓也, 中島健爾, 北智之, 武田匡史, 武田匡史, 溝口泰司, 林友鴻, 佐々木義浩, 畠山真弓, 田口久美子, 鷲尾健, 坂口志文, 錦織千佳子, 平田健一
    2015, 日本血管生物医学会学術集会プログラム・抄録集, 23rd

  • 共免疫抑制分子CTLA-4による動脈硬化抑制機構の解明
    松本卓也, 佐々木直人, 江本拓央, 溝口泰司, 林友鴻, 吉田尚史, 山下智也, 平田健一
    2015, 日本血管生物医学会学術集会プログラム・抄録集, 23rd

  • 冠動脈疾患患者に特徴的な腸内細菌叢の同定
    江本拓央, 山下智也, 佐々木直人, 林友鴻, 笠原和之, 淀井景子, 松本卓也, 溝口泰司, 平田健一
    2015, 日本循環器学会近畿地方会(Web), 120th(2) (2)

  • Subclinical Thyroid Dysfunction, Rather than Low-T3 Syndrome, is an Independent Predictor of Adverse Cardiac Events in Patients with Acute Decompensated Heart Failure
    Tomohiro Hayashi, Takuya Hasegawa, Hideaki Kanzaki, Akira Funada, Makoto Amaki, Takahiro Ohara, Yasuo Sugano, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai
    Nov. 2014, CIRCULATION, 130, English
    Summary international conference

  • SUBCLINICAL HYPOTHYROIDISM IN THE ACUTE DECOMPENSATED PHASE IS A NOVEL PREDICTOR FOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH HEART FAILURE
    Tomohiro Hayashi, Takuya Hasegawa, Hideaki Kanzaki, Akira Funada, Yasuo Sugano, Takahiro Ohara, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai
    Apr. 2014, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 63(12) (12), A770 - A770, English
    Summary international conference

  • アミオダロンの適正使用推進ための甲状腺機能異常の発症要因に関する検討
    木下佐昌子, 林友鴻, 大和幹枝, 和田恭一, 安斉俊久, 桑原健
    2014, 日本心不全学会学術集会プログラム・抄録集, 18th

  • 心不全患者における急性非代償期の潜在性甲状腺機能低下症は有害心イベントの独立した予測因子である
    林友鴻, 長谷川拓也, 神崎秀明, 舟田晃, 大原貴裕, 菅野康夫, 安田聡, 小川久雄, 安斉俊久
    (一社)日本心臓病学会, 2014, 日本心臓病学会学術集会抄録(CD-ROM), 62nd, O - 034, Japanese

  • Statistical Investigation of the Reference Value of ALT and Its Gender Differences-Are ALT (GPT) Levels Exceeding 30 IU/L Abnormal?-
    林孝和, 宇田真也, 林寿美, 林友鴻, 王おん玉
    2013, Progress in Medicine, 33(2) (2)

  • Levels of ALT (Alanine Aminotransferase) According to Generations/Age Groups (Changes in ALT Levels with Age)
    林孝和, 宇田真也, 林寿美, 林友鴻, 王おん玉
    2013, Progress in Medicine, 33(5) (5)

  • クリニカルシナリオ分類による心不全患者の臨床的特徴
    林友鴻, 長谷川拓也, 神崎秀明, 舟田晃, 菅野康夫, 大原貴裕, 石原正治, 清水渉, 安田聡, 小川久雄, 北風政史, 安斉俊久
    (一社)日本心臓病学会, 2013, 日本心臓病学会誌, 8(Supplement 1) (Supplement 1), 555 - 555, Japanese

  • 難治性の閉塞性肥大型心筋症に対して経皮的中隔心筋焼灼術が著効した1例
    幸田舞子, 佐田政隆, 伊勢孝之, 川端豊, 岩瀬俊, 門田宗之, 原知也, 太田理絵, 坂東美佳, 坂東左知子, 松浦朋美, 仁木敏之, 發知淳子, 冨田紀子, 上田由佳, 山口浩司, 八木秀介, 竹谷善雄, 山田博胤, 添木武, 若槻哲三, 赤池雅史, 岡崎誠司, 林友鴻, 長谷川拓也
    徳島医学会, 2013, 四国医学雑誌, 69(1/2) (1/2), 115 - 115, Japanese

  • 経皮的中隔心筋焼灼術が奏功した閉塞性肥大型心筋症の1例
    幸田舞子, 伊勢孝之, 川端豊, 門田宗之, 原知也, 太田理絵, 坂東美佳, 坂東左知子, 松浦朋美, 仁木敏之, 發知淳子, 山口浩司, 八木秀介, 岩瀬俊, 竹谷善雄, 山田博胤, 赤池雅史, 林友鴻, 長谷川拓也, 佐田政隆
    2013, 日本循環器学会中国地方会(Web), 102nd

  • 拡張不全における運動耐容能低下の病態とそれに対する運動療法の効果
    後藤葉一, 林友鴻, 藤野明子, 熊坂礼音, 荒川鉄雄, 中西道郎, 高濱博幸, 簗瀬正伸, 相原直彦, 野口輝夫, 高木洋
    (一社)日本心臓病学会, 2011, 日本心臓病学会誌, 6(Supplement 1) (Supplement 1), 151 - 151, Japanese

  • 背部痛を契機に診断された後縦隔血腫の一例
    林友鴻, 岡島年也, 吉牟田剛, 原田光一郎
    (一社)日本脈管学会, 2011, 脈管学, 51(Supplement) (Supplement), S175 - S176, Japanese

  • 運動時心拍増加不全(Chronotropic incompetence)は拡張不全患者に特有の運動耐容能低下機序か?
    林友鴻, 熊坂礼音, 高濱博幸, 荒川鉄雄, 中西道郎, 簗瀬正伸, 野口輝夫, 相原直彦, 後藤葉一
    2011, 心臓リハビリテーション, 16(2 Suppl.) (2 Suppl.)

  • 2 Stops of Warfarin Administration Preoperatively-Is It Necessary to Discontinue Warfarin for More Than 3 Days Prior to Invasive Procedures?-
    林孝和, 林寿美, 林友鴻
    2010, Progress in Medicine, 30(1) (1)

  • A Small Amount of Oral Vitamin K Can Urgently Suppress the Overuse of Warfarin Without Interruption
    林孝和, 林寿美, 林友鴻
    2010, Progress in Medicine, 30(1) (1)

  • Prediction of the Overdosage of Warfarin by Using the Differential Change (ΔINR/ΔDay) of the INR-Dangers at Introduction of Warfarin, When Prescribed in Accordance with the Directions in Japan-
    林孝和, 林寿美, 林友鴻
    2010, Progress in Medicine, 30(1) (1)

  • A Useful Method for Controlling Anticoagulant Effectiveness of Warfarin by Classifying PT-INRs (Warfarin is An Effective Drug, But It Should be Used Judiciously)
    林孝和, 林寿美, 林友鴻
    2010, Progress in Medicine, 30(4) (4)

  • 大動脈弁置換術後遠隔期にStanford A型急性大動脈解離を発症した1例
    林友鴻, 岡島年也, 原田光一郎, 吉牟田剛
    (有)科学評論社, 2010, 循環器内科, 68(3) (3), 291 - 296, Japanese

  • 僧房弁形成術後に出現した左室流出路狭窄に対して経皮的中隔心筋焼灼術が奏功した一症例
    林友鴻, 天木誠, 舟田晃, 高濱博幸, 長谷川拓也, 神崎秀明, 北風政史
    2010, 日本循環器学会近畿地方会(Web), 110th

  • 大動脈弁置換術後遠隔期にStanford A型急性大動脈解離を発症した一例
    林友鴻, 岡島年也, 吉牟田剛, 塘義明, 野々木宏
    2010, 日本循環器学会近畿地方会(Web), 109th(3) (3)

  • より望ましい高血圧管理におけるARBの役割-オルメサルタン40mgの有用性-
    林孝和, 林友鴻
    2009, Progress in Medicine, 29(2) (2)

  • 13年間の臨床経過中,PT-INR低下時にstrokeを繰り返したワルファリン療法下のNVAF患者
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(3) (3)

  • Why Most of Patients on Warfarin Have Not Been Anticoagulated to the Therapeutic Range in Japan?
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(6) (6)

  • Reconsideration of the Administration Dose of Vitamin K1 During Warfarin Therapy in Japan
    林孝和, 林寿美, 林友鴻, 高階經和
    2009, Progress in Medicine, 29(8) (8)

  • Dangers of Obeying the Directions of Warfarin Usage in Japan-Directions of Warfarin in Japan Need Immediate Corrections-
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(9) (9)

  • Major Complications Related to INRs During Warfarin Therapy-Do Japanese Elderly Patients on Warfarin Easily Develop Major Hemorrhage?-
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(11) (11)

  • 2 Stops of Warfarin Administration Preoperatively-Is It Necessary to Discontinue Warfarin for More Than 3 Days Prior to Invasive Procedures?-
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(12) (12)

  • ワルファリン導入期の出血合併症をいかに防ぐか-ワルファリン療法中のINR変動とワーファリン手帳-
    林孝和, 林寿美, 林友鴻
    2009, Progress in Medicine, 29(4) (4)

  • The Circadian Variation of PT-INR During Warfarin Therapy-Differences Between ‘A Single’ and ‘A Twice A Day’ Doses of Warfarin Medication-
    林孝和, 林寿美, 林友鴻, 高階經和
    2009, Progress in Medicine, 29(12) (12)

  • 消化器症状を伴うアレルギー性紫斑病の2症例
    田中秀憲, 菅もも子, 畑中宏史, 脇信也, 中村晃, 林友鴻, 別所宣洋, 宮地里江子, 松永亜紀子, 原田晋, 木崎智彦
    三田市民病院, 2008, 三田市民病院誌, 20, 21 - 25, Japanese

■ Books And Other Publications
  • 心不全栄養バイブル
    Joint work, 中外医学社, Jul. 2022, Japanese, ISBN: 9784498136762

  • 循環器ジャーナル Vol.68 No.1:U40世代が描く心不全診療の現状と未来 基礎研究を識り、臨床を素心深考する
    Joint work, 医学書院, Dec. 2019, ISBN: 4260029606

  • 症例で学ぶ循環器診療パーフェクトガイド
    Joint work, 中山書店, Apr. 2011, Japanese, ISBN: 9784521733692

■ Lectures, oral presentations, etc.
  • Uncovering The Role of Gut Microbiota in Amino Acid Metabolic Disturbances in Heart Failure Through Metagenomic Analysis.
    林 友鴻
    第86回日本循環器学会学術集会、YIA Clinical Research部門 優秀賞, Mar. 2022

  • Gut microbiome composition and plasma microbiome-related in patients with decompensated and compensated heart failure.
    林 友鴻
    第22回日本心不全学会学術集会、YIA審査講演, Aug. 2018

  • 紫外線B波照射はCD4陽性Foxp3陽性制御性T細胞を増幅し、アンギオテンシンII誘導性マウス大動脈瘤の形成を抑制する.
    林 友鴻
    第50回日本動脈硬化学会総会・学術集会, Jul. 2018

  • Alterations of gut microbiota composition and microbiota-associated metabolites in chronic heart failure
    林 友鴻
    第82回日本循環器学会学術集会, Mar. 2018

  • Gut microbiota and their relevant metabolites could be novel biomarkers and innovative therapeutic targets of chronic heart failure.
    林 友鴻
    第82回日本循環器学会学術集会、プレナリーセッション: 心不全の革新的予防戦略, Mar. 2018

  • 冠動脈疾患と心不全における腸内細菌の役割.
    林 友鴻
    心血管代謝週間CVMW 2017、シンポジウム: 腸内細菌叢と心血管代謝病, Dec. 2017
    [Invited]

  • A new ultraviolet-based immunomodulatory approach to abdominal aortic aneurysm.
    林 友鴻
    第49回日本動脈硬化学会総会・学術集会, Jul. 2017

  • Ultraviolet B Irradiation Inhibits the Development of Angiotensin II-Induced Abdominal Aortic Aneurysm Formation by Regulating Immuno-Inflammatory Responses.
    林 友鴻
    第81回日本循環器学会学術集会, Mar. 2017

  • Ultraviolet B Exposure Limits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice.
    林 友鴻
    第24回日本血管生物医学会学術集会, Dec. 2016

  • アンギオテンシンⅡ誘導性マウス大動脈瘤モデルを用いた、UVB照射による大動脈瘤抑制効果の検討.
    林 友鴻
    第48回日本動脈硬化学会総会・学術集会, Jul. 2016

  • Subclinical Hypothyroidism Is Common and an Independent Predictor of Adverse Outcomes in Patients with Acute Decompensated Heart Failure
    林 友鴻
    第79回日本循環器学会学術集会, Apr. 2015

  • Subclinical Thyroid Dysfunction, Rather than Low-T3 Syndrome, Is an Independent Predictor of Adverse Cardiac Events in Patients with Acute Decompensated Heart Failure.
    林 友鴻
    米国心臓協会 (AHA) 年次学術集会 2014, Nov. 2014

  • 心不全患者における急性非代償期の潜在性甲状腺機能低下症は有害心イベントの独立した予測因子である.
    林 友鴻
    第62回日本心臓病学会学術集会, Sep. 2014

  • Subclinical Hypothyroidism in the Acute Decompensated Phase Is a Novel Predictor for Adverse Cardiac Events in Patients with Heart Failure.
    林 友鴻
    第63回米国心臓病学会 (ACC) 年次学術集会 2014,, Mar. 2014

  • クリニカルシナリオ分類による心不全患者の臨床的特徴.
    林 友鴻
    第61回日本心臓病学会学術集会, Sep. 2013

  • In-stent restenosis following Everolimus-eluting stent.
    林 友鴻
    EuroPCR 2012, May 2012

  • Reservoir Function of Left Atrium Is Impaired in Patients with Symptomatic Severe Aortic Valve Stenosis.
    林 友鴻
    第61回米国心臓病学会 (ACC) 年次学術集会, Mar. 2012

  • Reservoir Function of Left Atrium Is Impaired in Patients with Symptomatic Severe Aortic Valve Stenosis.
    林 友鴻
    第76回日本循環器学会学術集会, Mar. 2012

  • Chronotropic Incompetence: Mechanism of Exercise Intolerance Specific to Patients with Elevated BNP and Preserved Ejection Fraction after Acute Myocardial Infarction?
    林 友鴻
    米国心臓協会 (AHA) 年次学術集会 2011, Dec. 2011

  • 背部痛を契機に診断された後縦隔血腫の一例.
    林 友鴻
    第52回日本脈管学会総会, Oct. 2011

  • Chronotropic Incompetence: Mechanism of Exercise Intolerance Specific to Patients with Elevated BNP and Preserved Ejection Fraction after Acute Myocardial Infarction?
    林 友鴻
    第75回日本循環器学会学術集会, Aug. 2011

  • Reservoir Function of Left Atrium Is Impaired in Patients with Heart Failure and Severe Mitral Regurgitation.
    林 友鴻
    第75回日本循環器学会学術集会, Aug. 2011

  • 運動時心拍増加不全 (Chronotropic incompetence) は拡張不全患者に特有の運動耐容能低下機序か?
    林 友鴻
    第17回日本心臓リハビリテーション学会学術集会, Jul. 2011

  • Reservoir Function of Left Atrium Is Impaired in Patients with Heart Failure and Severe Mitral Regurgitation.
    林 友鴻
    第60回米国心臓病学会 (ACC) 年次学術集会 2011, Apr. 2011

  • 僧房弁形成術後に出現した左室流出路狭窄に対して経皮的心筋焼灼術が奏功した一例.
    林 友鴻
    110回日本循環器学会近畿地方会, Nov. 2010

  • 大動脈弁置換術後遠隔期にStanford A型急性大動脈解離を発症した一例.
    林 友鴻
    第109回日本循環器学会近畿地方会, Jun. 2010

■ Affiliated Academic Society
  • 日本心臓リハビリテーション学会

  • 日本動脈硬化学会

  • 日本腫瘍循環器学会

  • 日本心不全学会

  • 日本心臓病学会

  • 日本プライマリ・ケア連合学会

  • 日本病院総合診療医学会

  • 日本内科学会

  • 日本循環器学会

■ Research Themes
  • たこつぼ型心筋症のリスク層別化と免疫学的制御による新規疾患治療法の開発
    林 友鴻
    日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 01 Apr. 2025 - 31 Mar. 2028

  • Investigation of the role of immunoinflammatory responses in atherosclerotic disease and development of novel immunotherapies
    SASAKI NAOTO, KASAHARA KAZUYUKI, EMOTO TAKUO, HAYASHI TOMOHIRO, MATSUMOTO TAKUYA, MIZOGUCHI TAIJI
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), 01 Apr. 2015 - 31 Mar. 2018
    Using atherosclerotic Foxp3+ regulatory T cell (Treg)-depleted mice, we provided direct evidence that Foxp3+ Tregs play a protective role in the development of atherosclerosis by regulating immunoinflammatory responses. Using atherosclerotic CTLA-4 (cytotoxic T lymphocyte antigen-4) transgenic mice, we demonstrated that CTLA-4 regulates atherosclerosis by suppressing pathogenic immune responses. We found that UVB irradiation reduced the development and related mortality of angiotensin II-induced abdominal aortic aneurysm in mice and that these protective effects were associated with systemic expansion of Foxp3+ Tregs and reduced inflammatory responses in aortic aneurysmal lesions.

TOP